Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate<sup>177</sup>Lu-Lilotomab Satetraxetan

Blakkisrud, Johan; Erik Holtedahl, Jon; Muftuler Løndalen, Ayca; Dahle, Jostein; Bach‐Gansmo, Tore; Holte, Harald; Nygaard, Stine; Kolstad, Arne; Stokke, Caroline

doi:10.2967/jnumed.117.195347

Public

Biodistribution and Dosimetry Results from a Phase 1 Trial of Therapy with the Antibody–Radionuclide Conjugate177Lu-Lilotomab Satetraxetan

Published in Journal of Nuclear Medicine • Aug 28, 2017

Authors:

Johan Blakkisrud

Jon Erik Holtedahl

Ayca Muftuler Løndalen

Abstract

177Lu-lilotomab satetraxetan is a novel antibody–radionuclide conjugate currently in a phase 1/2a first-in-humans dose escalation trial for patients with relapsed CD37-positive indolent non-Hodgkin lymphoma. The aim of this study was to investigate biodistribution and absorbed doses to organs at ris...

Subject

Biodistribution

Nuclear medicine

Dosimetry

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!